Drug Approval | October 09, 2022
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
The company increases its efficiency and is able to face the growing demand for its services.
The company increases its efficiency and is able to face the growing demand for its services.
Therapy recently approved in Canada under the brand name KORSUVA
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
100% efficacy against severe Covid-19 disease and hospitalizations
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Filing for WHO Emergency Use Authorisation this month
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Subscribe To Our Newsletter & Stay Updated
